Acute myocardial infarction (AMI) remains one of the leading causes of mortality globally, new-onset AF (NOAF) after AMI is a common complication of AMI, with an incidence of 6% to 21% [1], which is a well-established factor of worse short- and long-term prognosis [2,3]. However, the development of AF is multifactorial and the mechanisms are not well-understood [4,5]. Therefore, early identification of high-NOAF-risk patients is still of great clinical value.
